These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 10913809)

  • 21. The quality of clinical trials in neuroendocrine tumours; have we learnt from our mistakes? An evaluation of phase II and phase III clinical trials.
    Hayes AR; Chan DLH; Chan BA; Pavlakis N
    J Neuroendocrinol; 2021 Sep; 33(9):e13015. PubMed ID: 34397130
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical strategy for the development of angiogenesis inhibitors.
    Carter SK
    Oncologist; 2000; 5 Suppl 1():51-4. PubMed ID: 10804092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
    Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis.
    Smith CL; Jin Y; Raddad E; McNearney TA; Ni X; Monteith D; Brown R; Deeg MA; Schnitzer T
    Pharm Stat; 2019 Jan; 18(1):39-53. PubMed ID: 30321909
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II clinical trials in oncology: are we hitting the target?
    Ang MK; Tan SB; Lim WT
    Expert Rev Anticancer Ther; 2010 Mar; 10(3):427-38. PubMed ID: 20214523
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiple Histology Phase II Trials.
    Leblanc M; Rankin C; Crowley J
    Clin Cancer Res; 2009 Jul; 15(13):4256-62. PubMed ID: 19549777
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Designing phase II studies in cancer with time-to-event endpoints.
    Owzar K; Jung SH
    Clin Trials; 2008; 5(3):209-21. PubMed ID: 18559409
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An adaptive group sequential phase II design to compare treatments for survival endpoints in rare patient entities.
    Wunder C; Kopp-Schneider A; Edler L
    J Biopharm Stat; 2012; 22(2):294-311. PubMed ID: 22251175
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design.
    Taylor JM; Braun TM; Li Z
    Clin Trials; 2006; 3(4):335-48. PubMed ID: 17060208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design of Phase II cancer trials evaluating survival probabilities.
    Case LD; Morgan TM
    BMC Med Res Methodol; 2003 Apr; 3():6. PubMed ID: 12697051
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A flexible multi-stage design for phase II oncology trials.
    Tan MT; Xiong X
    Pharm Stat; 2011; 10(4):369-73. PubMed ID: 22328328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of power between randomized discontinuation design and upfront randomization design on progression-free survival.
    Fu P; Dowlati A; Schluchter M
    J Clin Oncol; 2009 Sep; 27(25):4135-41. PubMed ID: 19636018
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II trial design with growth modulation index as the primary endpoint.
    Wu J; Chen L; Wei J; Weiss H; Miller RW; Villano JL
    Pharm Stat; 2019 Mar; 18(2):212-222. PubMed ID: 30458583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Practice and progress in kidney cancer: methodology for novel drug development.
    Rini BI; Weinberg V; Small EJ
    J Urol; 2004 Jun; 171(6 Pt 1):2115-21. PubMed ID: 15126769
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A joint model for the dependence between clustered times to tumour progression and deaths: A meta-analysis of chemotherapy in head and neck cancer.
    Rondeau V; Pignon JP; Michiels S;
    Stat Methods Med Res; 2015 Dec; 24(6):711-29. PubMed ID: 22025414
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estimating the distribution of ratio of paired event times in phase II oncology trials.
    Chen L; Burkard M; Wu J; Kolesar JM; Wang C
    Stat Med; 2023 Feb; 42(3):388-406. PubMed ID: 36575855
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Setting the bar in phase II trials: the use of historical data for determining "go/no go" decision for definitive phase III testing.
    Vickers AJ; Ballen V; Scher HI
    Clin Cancer Res; 2007 Feb; 13(3):972-6. PubMed ID: 17277252
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials.
    Tang H; Foster NR; Grothey A; Ansell SM; Goldberg RM; Sargent DJ
    J Clin Oncol; 2010 Apr; 28(11):1936-41. PubMed ID: 20212253
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A hierarchical Bayesian design for randomized Phase II clinical trials with multiple groups.
    Yin J; Qin R; Sargent DJ; Erlichman C; Shi Q
    J Biopharm Stat; 2018; 28(3):451-462. PubMed ID: 28448747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.